NCT04144049View on ClinicalTrials.gov

A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

PHASE2CompletedINTERVENTIONAL

Enrollment

176

Participants

Timeline

Start Date

September 10, 2019

Primary Completion Date

March 10, 2020

Study Completion Date

April 23, 2020

Conditions

Submental Fat

Interventions

DRUG

MT921

Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.

DRUG

Placebo

Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.

Trial Locations (1)

06973

Chung-ang University Hospital, Seoul

All Listed Sponsors

lead

Medy-Tox

INDUSTRY

NCT04144049 - A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat | Biotech Hunter | Biotech Hunter